In our ongoing effort to work on possible prevention and treatments for COVID-19, I am pleased to share that we are getting ready to launch three new clinical trials to determine if drugs originally used for high blood pressure, Ebola and malaria can help people exposed to COVID-19. We expect to enroll the first patient as early as today.
One trial focuses on people who have been exposed to the virus but who do not have any symptoms. The second trial focuses on people who have tested positive for the virus but have mild symptoms and don’t require hospitalization. The third trial, which was recently approved by the NIH, is for hospitalized patients. You can read more details on these trials in today’s Star Tribune.
We are prepared to deliver care for people we serve with knowledge and willingness to take a stand and lead the national response to COVID-19 infection. The University of Minnesota has been designated by federal officials as the regional isolation and containment center for Minnesota, Wisconsin, Michigan and Illinois.
Lead with calm and confidence, and let us know how we can do better,
Jakub Tolar, MD, PhD
Campus Public Health Officer
Vice President for Clinical Affairs